Beckman Coulter Inc. on Friday posted a higher-than-expected second-quarter profit.
The Fullerton maker of medical diagnostic instruments, tests and other products posted a profit of $90.7 million before charges.
Second-quarter revenue grew 16% to $798.3 million. Beckman said that came about because of stronger results from its clinical diagnostics business and overseas sales.
Analysts expected Beckman to make $54.7 million on revenue of $756 million.
Beckman said its results included several one-time charges, including a $12 million research and development charge from a deal with rival Siemens Healthcare Diagnostics.
Including charges, Beckman’s net profit was $47.8 million, down 31.1% from 2007’s second quarter.
The second-quarter 2007 results included a one-time $40.6 million gain from a breakup fee from Biosite Inc., a San Diego diagnostics maker that Beckman pursued last year. Beckman eventually walked away from that deal when Biosite accepted a higher bid from Inverness Medical Innovations Inc.
The company also raised the low end of its full-year revenue forecast, saying it expects revenue growth of 12% to 13%, implying a range of $3.09 billion to $3.12 billion.
Previously, Beckman had expected sales growth of 11% to 13%. Beckman’s revenue totaled $2.76 billion in 2007.
Beckman also maintained its profit outlook of $223.2 million to $229.5 million this year.
Wall Street expects Beckman to have a full-year profit of $227 million on sales of $3.09 billion.
